http://seekingalpha.com/article/1660...ce=google_news

I listened to their conference call this morning and, frankly, I don't understand this transaction. Looks to me like Ceregene has totally thrown in the towel. They are getting 100,000 shares of a $10 stock, plus milestone payments? I must be missing something. They had $120 million of private equity invested in the company.

Interesting that there was almost no mention, other than the failed study, of CERE-120. All Sangamo was touting was CERE-110 (for AD). I guess we shouldn't be looking for any new CERE-120 trials anytime soon, if ever again.

i'm not qualified to comment on the bigger picture but they sure got em for peanuts. better than going bk like neurologix.

will be interesting to see if mjff and/or other researchers comment.